Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 91.6B 330M 283M 265M 242M 457M 31.49B 462M 3.13B 1.22B 15.89B 1.24B 1.21B 52.61B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 91.6B 330M 283M 265M 242M 457M 31.49B 462M 3.13B 1.22B 15.89B 1.24B 1.21B 52.61B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day+2.67%
1 week+4.32%
Current month+2.00%
1 month+1.82%
3 months+5.87%
6 months-10.32%
Current year-10.91%
1 week 899
Extreme 899
940
1 month 890.08
Extreme 890.08
945
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 2016-03-31
Director of Finance/CFO - 2019-10-31
Chief Operating Officer - 2024-05-31
Director TitleAgeSince
Chairman - 2022-05-29
Director/Board Member - 2009-02-28
Director/Board Member - 2014-06-03
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%+4.32%-21.42%+138.81% 321M
-1.06%+0.65%+77.42%+122.82% 1,111B
+0.53%+0.75%+53.10%+64.29% 658B
+0.48%+2.65%+28.06%+81.19% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.68%+4.24%+17.04% 256B
-0.36%+3.99%+53.31%+72.49% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+1.38%+3.72%+30.33%+93.56% 182B
Average +1.17%+3.05%+27.94%+62.56% 379.13B
Weighted average by Cap. +0.43%+2.20%+45.99%+72.30%

Financials

2024 2025
Net sales 68.18B 246M 211M 197M 180M 340M 23.44B 344M 2.33B 906M 11.82B 923M 903M 39.16B 75.4B 272M 233M 218M 199M 376M 25.92B 380M 2.57B 1B 13.08B 1.02B 999M 43.3B
Net income 5.23B 18.87M 16.17M 15.15M 13.84M 26.12M 1.8B 26.38M 179M 69.58M 908M 70.86M 69.32M 3.01B 7.97B 28.72M 24.61M 23.06M 21.07M 39.76M 2.74B 40.15M 272M 106M 1.38B 108M 106M 4.58B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
26-08-25 PKR 935.61 +2.67% 122,077
26-08-24 PKR 911.28 +0.13% 15,074
26-08-21 PKR 910.11 +0.64% 22,939
26-08-20 PKR 904.28 +0.48% 9,956
26-08-19 PKR 900.00 +0.35% 9,821
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
935.61
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABOT Stock